washington  reuters    the largest lobbying organization for pharmaceutical companies began running tv ads on monday morning to improve the industry s image as criticism from u s  president donald trump increases  the industry is touting developments in science by pharmaceutical companies and will spend  tens of millions  on television commercials  according to an announcement on monday by officials of lobbying group phrma  a spokesman did not provide a specific amount   pharmaceutical companies may be facing their most difficult time ahead as criticism about the price of drugs continues to increase  in a news conference this month  trump said drug manufacturers were  getting away with murder  because of their pricing   additionally  drug manufacturers were considered winners when the affordable care act became law because more people had increased access to prescriptions  a repeal of the law often known as obamacare could mean many people losing insurance could not afford to purchase drugs   phrma ceo stephen ubl cast the  go boldly  campaign as an effort to refocus the discussion about the strides in research  but he acknowledged the industry was at the center of criticism   we take the concerns that have been raised by the president very seriously   ubl said   we think there are pragmatic policy solutions  and we look forward to working with the administration   while outspoken while the affordable care act was being drafted  phrma has largely remained quiet during the early discussions about whether the law should be repealed and replaced   planning for the group s campaign began six months ago  well before the november presidential election  according to  spokesman robert zirkelbach       like many organizations  the group signaled it expected democrat hillary clinton was going to win and began planning to push back at her calls for capping drug prices  it continued with plans for the campaign  which ubl said would have been the same had clinton won  even after trump was elected   the group also released a four part regulatory and legislative agenda that it said would be part of an extensive lobbying campaign  including advocating for changes to the food and drug administration and the ability for drugmakers to coordinate with insurance companies when developing new treatments  the campaign makes almost no mention of the repeal of obamacare    this campaign  is not aimed at any one legislative issue   ubl said   